CRSP - CIK 0001674416
CRISPR Therapeutics AG (CRSP) reported revenue of $3.51M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $3.51M | -90.6% |
| FY 2024 | $37.31M | -89.9% |
| FY 2023 | $371.21M | +30885.5% |
| FY 2022 | $1.20M | -99.9% |
| FY 2021 | $914.96M | +127154.9% |
| FY 2020 | $719.00K | -99.8% |
| FY 2019 | $289.59M | +9169.8% |
| FY 2018 | $3.12M | -92.4% |
| FY 2017 |
CRISPR Therapeutics AG (CRSP) reported revenue of $3.51M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, CRISPR Therapeutics AG's revenue grew from $247.00K to $3.51M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $41.00M |
| +693.9% |
| FY 2016 | $5.16M | +1990.7% |
| FY 2015 | $247.00K | - |